324 related articles for article (PubMed ID: 18203952)
21. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
Yang ZZ; Novak AJ; Stenson MJ; Witzig TE; Ansell SM
Blood; 2006 May; 107(9):3639-46. PubMed ID: 16403912
[TBL] [Abstract][Full Text] [Related]
22. High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.
Arlt A; von Bonin F; Rehberg T; Perez-Rubio P; Engelmann JC; Limm K; Reinke S; Dullin C; Sun X; Specht R; Maulhardt M; Linke F; Bunt G; Klapper W; Vockerodt M; Wilting J; Pukrop T; Dettmer K; Gronwald W; Oefner PJ; Spang R; Kube D
Mol Oncol; 2020 Mar; 14(3):571-589. PubMed ID: 31825135
[TBL] [Abstract][Full Text] [Related]
23. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
24. New molecular targets in Hodgkin and Reed-Sternberg cells.
Sadaf H; Ambroziak M; Binkowski R; Kluebsoongnoen J; Paszkiewicz-Kozik E; Steciuk J; Markowicz S; Walewski J; Sarnowska E; Sarnowski TJ; Konopinski R
Front Immunol; 2023; 14():1155468. PubMed ID: 37266436
[TBL] [Abstract][Full Text] [Related]
25. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.
Aldinucci D; Lorenzon D; Cattaruzza L; Pinto A; Gloghini A; Carbone A; Colombatti A
Int J Cancer; 2008 Feb; 122(4):769-76. PubMed ID: 17935139
[TBL] [Abstract][Full Text] [Related]
26. Transactivation of the ICAM-1 gene by CD30 in Hodgkin's lymphoma.
Uchihara JN; Matsuda T; Okudaira T; Ishikawa C; Masuda M; Horie R; Watanabe T; Ohta T; Takasu N; Mori N
Int J Cancer; 2006 Mar; 118(5):1098-107. PubMed ID: 16152613
[TBL] [Abstract][Full Text] [Related]
27. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma.
Tzankov A; Matter MS; Dirnhofer S
Pathobiology; 2010; 77(6):301-8. PubMed ID: 21266828
[TBL] [Abstract][Full Text] [Related]
28. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.
Gandhi MK; Lambley E; Duraiswamy J; Dua U; Smith C; Elliott S; Gill D; Marlton P; Seymour J; Khanna R
Blood; 2006 Oct; 108(7):2280-9. PubMed ID: 16757686
[TBL] [Abstract][Full Text] [Related]
29. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab in the Treatment of Hodgkin Lymphoma.
Ansell SM
Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
[TBL] [Abstract][Full Text] [Related]
31. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.
Tiacci E; Döring C; Brune V; van Noesel CJ; Klapper W; Mechtersheimer G; Falini B; Küppers R; Hansmann ML
Blood; 2012 Nov; 120(23):4609-20. PubMed ID: 22955914
[TBL] [Abstract][Full Text] [Related]
32. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.
Dorfman DM; Brown JA; Shahsafaei A; Freeman GJ
Am J Surg Pathol; 2006 Jul; 30(7):802-10. PubMed ID: 16819321
[TBL] [Abstract][Full Text] [Related]
33. Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions.
Nagamatsu T; Schust DJ; Sugimoto J; Barrier BF
Hum Reprod; 2009 Dec; 24(12):3160-71. PubMed ID: 19729380
[TBL] [Abstract][Full Text] [Related]
34. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
[TBL] [Abstract][Full Text] [Related]
35. Follicular peripheral T-cell lymphoma expands the spectrum of classical Hodgkin lymphoma mimics.
Moroch J; Copie-Bergman C; de Leval L; Plonquet A; Martin-Garcia N; Delfau-Larue MH; Molinier-Frenkel V; Belhadj K; Haioun C; Audouin J; Swerdlow SH; Marafioti T; Gaulard P
Am J Surg Pathol; 2012 Nov; 36(11):1636-46. PubMed ID: 23073322
[TBL] [Abstract][Full Text] [Related]
36. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
37. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
38. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
39. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.
Gandhi MK; Moll G; Smith C; Dua U; Lambley E; Ramuz O; Gill D; Marlton P; Seymour JF; Khanna R
Blood; 2007 Aug; 110(4):1326-9. PubMed ID: 17438085
[TBL] [Abstract][Full Text] [Related]
40. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
